ABSTRACT

Background

In a real-world analysis (RWA) conducted in the United States (US), median international units (IUs) of extended half-life (EHL) recombinant coagulation factor VIII (rFVIII) dispensed were 10% to 45% greater than standard half-life (SHL) rFVIII. The mean IUs of each rFVIII dispensed quarterly were obtained from two databases (N = 776).

Methods

A probabilistic model in a 1-year time horizon was used in order to analyze the cost comparison of SHL and EHL rFVIII products in Spain. In this analysis, mean IUs were those of the RWA, and frequency of use and prices for each rFVIII were obtained from sales estimates based on Spanish sources (IQVIA; €, 2019)

Results

Data showed an average annual savings per patient of €11,227 for SHL rFVIII versus EHL rFVIII products, with a savings probability of 75.5%. The results were stable in the sensitivity analyses. Not switching treatment from SHL to EHL rFVIII resulted in greater savings per patient (€53,078), with a savings probability of 99.9%. Considering the frequency of rFVIII dispensation in the US, annual savings per patient would increase to €16,350 in Spain, with a savings probability of 79.9%.

Conclusions

According to this model, use of SHL rFVIII versus EHL rFVIII products could lead to savings for the Spanish National Health System.

中文翻译：

---

在西班牙接受标准半衰期或延长半衰期 FVIII 治疗的血友病 A 患者的费用

摘要

背景

在美国 (US) 进行的真实世界分析 (RWA) 中，分配的延长半衰期 (EHL) 重组凝血因子 VIII (rFVIII) 的中位国际单位 (IU) 比标准半衰期高 10% 至 45% -生命（SHL）rFVIII。每季度分配的每个 rFVIII 的平均 IU 来自两个数据库 (N = 776)。

方法

使用 1 年时间范围内的概率模型来分析 SHL 和 EHL rFVIII 产品在西班牙的成本比较。在该分析中，平均 IU 是 RWA 的平均值，每个 rFVIII 的使用频率和价格来自基于西班牙来源的销售估算（IQVIA；€，2019）

结果

数据显示，SHL rFVIII 与 EHL rFVIII 产品相比，每位患者平均每年节省 11,227 欧元，节省概率为 75.5%。结果在敏感性分析中是稳定的。不将治疗从 SHL 转换为 EHL rFVIII 可使每位患者节省更多（53,078 欧元），节省概率为 99.9%。考虑到在美国分配 rFVIII 的频率，西班牙每位患者每年节省的费用将增加到 16,350 欧元，节省的概率为 79.9%。

结论

根据该模型，使用 SHL rFVIII 与 EHL rFVIII 产品相比，可以为西班牙国家卫生系统节省开支。